Corvus Pharmaceuticals’ Ian McCaffery, PhD to Present at Rational Combinations 360° June 23-24, New York
The conference will encompass the most up-to-date developments from the business, clinical and scientific perspectives related to progressing and prioritizing the best combination cancer treatments for individual patients and tumor types.
Dr. McCaffery is co-chairing the conference as well as the Scientific Section on Day 2. On the 24th, he will also present data supporting CPI-444 as a checkpoint inhibitor both as a single agent as well as in combination with other agents that modulate tumor immunity by a variety of mechanisms in a talk entitled: “CPI-444, an oral checkpoint inhibitor of adenosine mediated suppression of tumor immunity.” Corvus’s ongoing clinical study evaluating CPI-444 as a single agent as well as in combination with the anti-PD-L1 antibody atezolizumab will also be discussed.
Dr. McCaffery is the vice president of translational sciences for
About CPI-444
CPI-444, Corvus’s lead checkpoint inhibitor, is designed to disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is a small molecule that is taken orally. CPI-444 is being evaluated in a multicenter Phase 1/1b clinical trial in patients with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and in combination with TECENTRIQ™ (atezolizumab), Genentech's investigational cancer immunotherapy. TECENTRIQ™ (atezolizumab) is a fully humanized monoclonal antibody targeting protein programmed cell death ligand 1 (PD-L1). Corvus is conducting the trial with Genentech, a member of the
About
Investor Contact:Leiv Lea Chief Financial Officer LLea@corvuspharma.com 650-900-4522 Media Contact:Julie Normart ,W2O Group 415-946-1087 jnormart@w2ogroup.com